AUSTRALIA AND NEW ZEALAND SURGICAL AND RESPIRATORY MASK MARKET ANALYSIS

Australia & New Zealand Surgical and respiratory Mask Market is estimated to be valued at US$ 195.54 Mn in 2023 and is expected to exhibit a CAGR of 6.9% during the forecast period (2023-2030).

Analysts’ Views on Australia & New Zealand Surgical and respiratory Mask Market:

The use of surgical and respiratory masks is becoming more and more necessary due to the rising prevalence of infectious and lung disorders which tends to drive the Australia & New Zealand surgical and respiratory mask market over the forecast period. For instance, over 570,000 people, one in eight New Zealanders, take asthma medicine, according to the Asthma and Respiratory Foundation NZ (New Zealand). According to estimates, 162 out of every 100,000 people had severe bronchiectasis, or 8,053. Children of Mori descent experience hospitalization rates for pneumonia that are 1.6 times higher than those of other New Zealanders, 3.7 times higher than those of Pacific Islanders, and 1.2 times higher than those of Asians.

Figure 1. Australia & New Zealand Surgical and Respiratory Mask Market Value (US$ Mn) & Y-o-Y Growth (%), 2018-2030

To learn more about this report, request a free sample copy

Figure 2. Australia & New Zealand Surgical and respiratory Mask Market Share (%), by Product Type, 2023

To learn more about this report, request a free sample copy

Australia & New Zealand Surgical and respiratory Mask Market – Driver

Increasing number of surgical procedures

Prevalence of increasing surgeries leads to admissions in hospitals which tends to the use of surgical masks and respiratory masks by the general practitioners or by patients. For instance, according to the Australian Institute of Health and Welfare, Emergency admissions involving surgery accounted for 387,000 hospitalizations in 2020–2021; 86% (332,000) of these occurred in public hospitals while 14% (54,900) did so in private ones. the top three causes of surgery-related emergency admissions. Some jurisdictions may expect significant increases in emergency department traffic between 2020 and 21 as a result of the activity's 6.9% growth from 2019 to 2020.

Australia & New Zealand Surgical and respiratory Mask Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets.

The COVID-19 pandemic had a positive impact on the Australia & New Zealand surgical and respiratory mask market owing to the increasing number of infectious diseases such as flu and viral during COVID time. The COVID-19 pandemic has led to an acute shortage of surgical and respirator masks. In March 2020, The Centers for Disease Control and Prevention, a national public health agency of the United States stated that consideration can be made to use N95 respirators beyond the manufacturer-designated shelf life for the care of patients with COVID-19, tuberculosis, measles, and varicella.

Australia & New Zealand Surgical and respiratory Mask Market Segmentation:

The Australia & New Zealand surgical and respiratory mask market is segmented into product type, and sales channel.

By Product Type, the market is segmented into respiratory mask and surgical mask. Out of which, respiratory mask is expected to hold a dominant position in the Australia & New Zealand surgical and respiratory mask market during the forecast period and this is attributed to an increase in surgical procedures, product innovation, and growth in concern regarding health & hygiene.

By Sales channel, the market is segmented into offline and online. Out of which, the online segment is expected to hold a dominant position in the Australia & New Zealand surgical and respiratory mask market during the forecast period and this is attributed to the increasing e-commerce attention and meet the demand for masks all over Australia and New Zealand.

Among all the segmentations, the product type has the highest potential due to the increasing production and increase in healthcare facilities. For instance, in September 2020, according to the Australian Government Department of Health and Aged Care, Particulate Filter Respirators (PFRs), also known as filtering facepiece respirators or disposable respirators, are a component of airborne precautions and are comprised of multiple layers which filter particles through mechanical impaction and electrostatic capture (58). PFRs are designed to provide a good facial fit to minimize aerosol contamination of the mucous membranes of the nose and mouth.

Australia & New Zealand Surgical and respiratory Mask Market: Key Developments

In May 2020, First Graphene, the global producer of advanced graphene products, and planarTECH Ltd, a global producer of graphene process equipment and graphene-enabled products, agreed to collaborate on graphene-enhanced personal protective equipment (PPE) products.

In December 2021, EBOS Group Limited (EBOS), the marketer, wholesaler, and distributor of medical, and pharmaceutical products in Australia through its wholly-owned subsidiary EBOS Medical Devices Australia Pty Limited, acquired Australian Pacific Health Supplies TopCo1 Pty Limited and its subsidiaries. EBOS is an ASX (Australian Securities Exchange) and NZX  (New Zealand Exchange). Pacific Health Group comprises interests in two businesses that have a presence in Australia, being LifeHealthcare and Australian Biotechnologies, and is a manufacturer and distributor of allografts and distributor of medical devices.

In June 2020, EBOS Group Limited, the marketer, wholesaler, and distributor of medical, and pharmaceutical products in Australia, announced that a mutually beneficial outcome with the Federal Government has been achieved following the recent execution of the 7th Community Pharmacy Agreement. EBOS national healthcare wholesaler and wholly-owned subsidiary Symbion, together with members of the National Pharmaceutical Services Association (NPSA), a part of Australia’s complex health infrastructure has been actively engaged in negotiations with the Department of Health and Federal Minister for Health.

In November 2022, according to the Australian Government Department of Health and Aged Care, the Australian guidelines for the prevention and control of infection in healthcare (the guidelines) described the best way to prevent and reduce infections occurring in healthcare settings including resistant infections. The guidelines include how to manage common infectious agents, for example, gastrointestinal viruses, and evolving infectious agents, for example, influenza or multi-drug resistant organisms.

Australia & New Zealand Surgical and respiratory Mask Market: Key Trends

On June 1, 2023, the Australian Government provided a total of US$ 3.2 million in the October 2022-23 Budget for the preparations to establish an Australian CDC (Centers for Disease Control and Prevention). In November and December 2022, the Australian Government invited select stakeholders to join a targeted consultation process exploring the roles and responsibilities of an Australian CDC., which included workshops held in each capital city, a virtual workshop, and written responses to the CDC consultation paper.

In Australia, healthcare expenditure in private hospitals is higher than that of public hospitals. For instance, in November 2022, according to the American Institute of Health and Welfare, in 2020–21, hospitalization rates varied across levels of socio-economic disadvantage and remoteness for public and private hospitals. For public hospitals, the highest rates of hospitalization were for patients living in the most disadvantaged areas (305 hospitalizations per 1,000 population) with rates generally decreasing as the level of disadvantage decreases. For private hospitals, the highest rates were for patients living in the least disadvantaged areas (238 hospitalizations per 1,000 population) with hospitalization rates decreasing as the level of disadvantage increases.

Australia & New Zealand Surgical and respiratory Mask Market: Restraints

Limited product availability and product visibility

Due to long-term contracts between suppliers and manufacturers, product visibility is constrained in both nations. This has made it more difficult for other multinational firms who compete in the market for medical goods to collaborate with them. Whereas the limited product availability in the pandemic time also restricted the growth of the market. So, increase in the distribution agreement with the key players along with product availability in the market. For instance, in April 2020, according to the Queensland Government of Northeastern Australia, an independent government-owned statutory body, Australia is experiencing a shortage of disposable particulate respirators as a result of rising demand from the public and health care professionals, as well as the temporary closure of numerous Chinese manufacturers. Moreover, the number of disposable medical product suppliers in Australia and New Zealand is low, which limits product differentiation and restrains market growth.

Australia & New Zealand Surgical and respiratory Mask Market - Key Players

Major players operating in the Australia & New Zealand surgical and respiratory mask market include 3M Company, Smith & Nephew Plc., O&M Halyard or its affiliates, Mölnlycke Health Care AB, Medline Industries, Inc., Ansell LTD, and WPT Nonwovens Corp.

Definition: During surgical procedures, surgical masks are used to cover the mouth and nose. Bacterial Filtration Efficiency (BFE), Particulate Filtration Efficiency (PFE), Pressure Difference (Pa), and Splash Protection (mm Hq) are used to classify masks. For routine patient care, simple surgical masks are utilized. Basic surgical masks just lower the chance of infection and have not been proven to protect against any germs. Respirators protect from exposure to airborne particles. In healthcare, protects from exposure to biological aerosols including viruses and bacteria. A respirator is designed to protect the wearer from inhaling airborne contaminants such as dust, fumes, vapors, and infectious agents associated with inhaling small and large particle droplets; guidance on appropriate selection and use is covered by (Occupational Safety and Health Administration) OSHA’s respiratory protection and PPE (Personal protective equipment) standards. Both types of personal protective equipment (PPE) can be used for infection control; however, only respirators can be used for respiratory protection against airborne chemical hazards. Because both, respirators and surgical masks, are used in healthcare settings, employers and workers must understand the differences between them.